ELTP (Elite Pharmaceuticals) Interest Expense : $-0.85 Mil (TTM As of Sep. 2024)

View and export this data going back to 2009. Start your Free Trial

What is Elite Pharmaceuticals Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Elite Pharmaceuticals's interest expense for the three months ended in Sep. 2024 was $ -0.26 Mil. Its interest expense for the trailing twelve months (TTM) ended in Sep. 2024 was $-0.85 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Elite Pharmaceuticals's Operating Income for the three months ended in Sep. 2024 was $ 3.49 Mil. Elite Pharmaceuticals's Interest Expense for the three months ended in Sep. 2024 was $ -0.26 Mil. Elite Pharmaceuticals's Interest Coverage for the quarter that ended in Sep. 2024 was 13.67. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Elite Pharmaceuticals Interest Expense Historical Data

The historical data trend for Elite Pharmaceuticals's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Elite Pharmaceuticals Interest Expense Chart

Elite Pharmaceuticals Annual Data

Trend

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Mar24

Interest Expense

Get a 7-Day Free Trial

-0.36

-0.26

-0.19

-1.11

-0.59

Elite Pharmaceuticals Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Interest Expense	Get a 7-Day Free Trial															-0.13	-0.12	-0.22	-0.25	-0.26

Elite Pharmaceuticals Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.85 Mil.

Elite Pharmaceuticals (OTCPK:ELTP) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Elite Pharmaceuticals's Interest Expense for the three months ended in Sep. 2024 was $-0.26 Mil. Its Operating Income for the three months ended in Sep. 2024 was $3.49 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Sep. 2024 was $6.24 Mil.

Elite Pharmaceuticals's Interest Coverage for the quarter that ended in Sep. 2024 is calculated as

Interest Coverage	=	-1	*	Operating Income (Q: Sep. 2024 )	/	Interest Expense (Q: Sep. 2024 )
	=	-1	*	3.485	/	-0.255
	=	13.67

The higher the ratio, the stronger the company's financial strength is.

Elite Pharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Elite Pharmaceuticals Inc (OTCPK:ELTP) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

N/A

Address

165 Ludlow Avenue, Northvale, NJ, USA, 07647

Website

https://www.elitepharma.com

Elite Pharmaceuticals Inc is a pharmaceutical company. It is principally engaged in the development and manufacture of oral, controlled-release products, using proprietary know-how and technology. The company's operating segment includes Abbreviated New Drug Applications (ANDA) and New Drug Applications (NDA). It generates maximum revenue from the ANDA segment. The company focuses on developing pain management products; manufacturing a line of generic pharmaceutical products with approved Abbreviated New Drug Applications; developing additional generic pharmaceutical products; development of other products in its pipeline including the products with its partners; and commercialization of new products.

Executives

Douglas Plassche	officer: Executive VP of Operations	165 LUDLOW AVE., NORTHVALE NJ 07647
Mark N Pellegrino	officer: CFO, Secretary, Treasurer	165 LUDLOW AVE, NORTHVALE NJ 07647
Kirko Kirkov	officer: Chief Commercial Officer	165 LUDLOW AVE, NORTHVALE NJ 07647
Chen Robert C J	officer: CFO, Secretary, Treasurer	165 LUDLOW AVENUE, NORTHVALE NJ 07647
Marc Bregman	officer: CFO, Secretary, Treasurer	C/O ELITE PHARMACEUTICALS, INC., 165 LUDLOW AVENUE, NORTHVALE NJ 07647
Eugene M Pfeifer	director	C/O ELITE PHARMACEUTICALS, INC, 165, NORTHVALE NJ 07647
Davis S Caskey	director	C/O ELITE PHARMACEUTICALS, INC, 165 LUDLOW AVE, NORTHVALE NJ 07647
Jerry Treppel	director	93 SETON HIGHLANDS, PLYMOUTH MA 02360
Mikah Pharma, Llc	10 percent owner	165 LUDLOW AVE., NORTHVALE NJ 07647
Jeenarine Narine	director, 10 percent owner	C/O EPIC PHARMA, LLC, 227-15 NORTH CONDUIT AVENUE, LAURELTON NY 11413
Ashok G Nigalaye	director, 10 percent owner, officer: Chief Scientific Officer	C/O EPIC PHARMA, LLC, 227-15 NORTH CONDUIT AVENUE, LAURELTON NY 11413
Epic Pharma Llc	10 percent owner	227-15 NORTH CONDUIT AVE, LAURELTON NY 11413-3134
Epic Investments, Llc	10 percent owner	227-15 NORTH CONDUIT AVENUE, LAURELTON NY 11413
Nasrat A Hakim	director, 10 percent owner, officer: President & CEO	C/O ELITE PHARMACEUTICALS, INC., 165 LUDLOW AVE., NORTHVALE NJ 07647
Jeffrey A Whitnell	director	C/O ELITE PHARMACEUTICALS, INC, 165 LUDLOW AVENUE, NORTHVALE NJ 07647